Cancer patients at risk of drug interactions.
D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D016907:Adverse Drug Reaction Reporting Systems; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000897:Anti-Ulcer Agents / Q000009:adverse effects; D000925:Anticoagulants / Q000009:adverse effects; D000932:Antiemetics / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D002170:Canada; D004347:Drug Interactions; D011307:Drug Prescriptions / Q000592:standards*; D004359:Drug Therapy, Combination; D006785:Hospitals, University; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors
D000305:Adrenal Cortex Hormones; D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D000925:Anticoagulants; D000932:Antiemetics; D000959:Antihypertensive Agents; D000970:Antineoplastic Agents